Eledon Pharmaceuticals, Inc. (ELDN)
ELDNNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.13
-0.2350 (-9.94%) today
At the close, Nov 13, 4:00 PM ET. After hours $2.15 +1.65%
- Market cap
- $178.63m
- P/E
- –
- EPS, last 4 quarters
- $-0.6300
- Dividend yield
- –
- Day range
- $2.07 to $2.51
- 52-week range
- $1.35 to $4.49
- Average volume
- –
- Previous close
- $2.37
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $9.00, +322.5% from here
Earnings
next estimate $-0.1900Next report
Dec 2025
+50.0%
Mar 2026
+27.3%
Jun 2026
0.0%
Sep 2026
+10.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$19.07m | -$21.48m | -$21.18m | -$22.87m |
| Net income | -$17.46m | -$10.45m | -$39.02m | -$31.63m |
News
8 latest- Eledon Announces Updated BESTOW Long-Term Data, Wins FDA Fast Track Designation For Tegoprubart RTTNews · Sep 22, 2026
- Eledon Advances Tegoprubart In Islet Cell And Kidney Transplant Programs RTTNews · Sep 3, 2026
- NewcelX Prices Private Placement At $4.03 Per Share; Advances NCEL-101 In Pre-IND FDA Meeting RTTNews · Aug 3, 2026
- Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired RTTNews · Jun 26, 2026
- Natera, Eledon Partner On Kidney Transplant Monitoring Test For Phase 3 Trial; Stock Up RTTNews · Jun 25, 2026
- Eledon Presents New Long-Term Data Of Tegoprubart From Phase 2 Kidney Transplant Study; Stock Down RTTNews · Jun 23, 2026
- Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?Zacks · Jun 16, 2026
- Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?Zacks · May 29, 2026
The company
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- eledon.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.